INZY Stock Overview
A clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Inozyme Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.29 |
| 52 Week High | US$7.80 |
| 52 Week Low | US$1.24 |
| Beta | 1.29 |
| 1 Month Change | -35.34% |
| 3 Month Change | -63.66% |
| 1 Year Change | -76.16% |
| 3 Year Change | -81.83% |
| 5 Year Change | n/a |
| Change since IPO | -92.65% |
Recent News & Updates
Recent updates
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?
Nov 17
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet?
Aug 03Inozyme: Q4 Of 2024 Phase 1 INZ-701 Data Could Lead To Indication Expansion
Jul 30Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Apr 11Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward
Mar 08Inozyme Pharma GAAP EPS of -$0.38
Aug 15Inozyme Pharma releases positive early-stage data on candidate for ABCC6 Deficiency
Jul 19Will Inozyme Pharma (NASDAQ:INZY) Spend Its Cash Wisely?
Jul 12We're Keeping An Eye On Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
Apr 06Here's Why We're Not Too Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Situation
Dec 22Companies Like Inozyme Pharma (NASDAQ:INZY) Are In A Position To Invest In Growth
Sep 08We're Not Very Worried About Inozyme Pharma's (NASDAQ:INZY) Cash Burn Rate
May 22Inozyme Pharma's INZ-701 shows potential for the treatment for ABCC6 deficiency
May 07We're Hopeful That Inozyme Pharma (NASDAQ:INZY) Will Use Its Cash Wisely
Feb 06
Inozyme Pharma on go with early-stage INZ-701 trial in a rare calcification disorder
Jan 04Inozyme Pharma (INZY) Investor Presentation - Slideshow
Dec 03Inozyme Pharma EPS misses by $1.02
Nov 12Shareholder Returns
| INZY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.1% | -1.3% | 1.2% |
| 1Y | -76.2% | -4.5% | 21.0% |
Return vs Industry: INZY underperformed the US Biotechs industry which returned -4.5% over the past year.
Return vs Market: INZY underperformed the US Market which returned 21% over the past year.
Price Volatility
| INZY volatility | |
|---|---|
| INZY Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 18.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INZY's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INZY's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 59 | Doug Treco | www.inozyme.com |
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company’s lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products.
Inozyme Pharma, Inc. Fundamentals Summary
| INZY fundamental statistics | |
|---|---|
| Market cap | US$89.94m |
| Earnings (TTM) | -US$96.49m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs INZY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INZY income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$96.49m |
| Earnings | -US$96.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 55.1% |
How did INZY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/11 23:05 |
| End of Day Share Price | 2025/02/11 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Inozyme Pharma, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Edward White | H.C. Wainwright & Co. |
| Maurice Raycroft | Jefferies LLC |